FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 235 filers reported holding FATE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $47,509 | -54.7% | 22,410 | +1.6% | 0.00% | -100.0% |
| Q2 2023 | $104,991 | -18.2% | 22,057 | -2.1% | 0.00% | 0.0% |
| Q1 2023 | $128,387 | -41.9% | 22,524 | +2.9% | 0.00% | -50.0% |
| Q4 2022 | $220,941 | -53.1% | 21,897 | +4.2% | 0.00% | -60.0% |
| Q3 2022 | $471,000 | -9.1% | 21,007 | +0.5% | 0.01% | 0.0% |
| Q2 2022 | $518,000 | -35.3% | 20,906 | +1.2% | 0.01% | -16.7% |
| Q1 2022 | $801,000 | -33.2% | 20,651 | +0.8% | 0.01% | -33.3% |
| Q4 2021 | $1,199,000 | -1.3% | 20,495 | +0.0% | 0.01% | -10.0% |
| Q3 2021 | $1,215,000 | -31.4% | 20,492 | +0.5% | 0.01% | -28.6% |
| Q2 2021 | $1,770,000 | +5.7% | 20,394 | +0.4% | 0.01% | -6.7% |
| Q1 2021 | $1,675,000 | -8.6% | 20,317 | +0.8% | 0.02% | -11.8% |
| Q4 2020 | $1,832,000 | +144.3% | 20,148 | +7.4% | 0.02% | +142.9% |
| Q3 2020 | $750,000 | +60.3% | 18,753 | +37.4% | 0.01% | 0.0% |
| Q2 2020 | $468,000 | +48.6% | 13,649 | -3.9% | 0.01% | +40.0% |
| Q1 2020 | $315,000 | – | 14,197 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |